NASDAQ:IPHA Innate Pharma (IPHA) Stock Price, News & Analysis $1.88 -0.02 (-1.06%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Innate Pharma Stock (NASDAQ:IPHA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Innate Pharma alerts:Sign Up Key Stats Today's Range$1.83▼$1.9150-Day Range$1.71▼$2.4452-Week Range$1.70▼$3.15Volume6,627 shsAverage Volume9,202 shsMarket Capitalization$151.82 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingStrong Buy Company OverviewInnate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Read More… Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Innate Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks56th Percentile Overall ScoreIPHA MarketRank™: Innate Pharma scored higher than 56% of companies evaluated by MarketBeat, and ranked 416th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingInnate Pharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageInnate Pharma has only been the subject of 2 research reports in the past 90 days.Read more about Innate Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Innate Pharma are expected to grow in the coming year, from ($0.98) to ($0.94) per share.Price to Book Value per Share RatioInnate Pharma has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.07% of the outstanding shares of Innate Pharma have been sold short.Short Interest Ratio / Days to CoverInnate Pharma has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Innate Pharma has recently decreased by 18.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInnate Pharma does not currently pay a dividend.Dividend GrowthInnate Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.07% of the outstanding shares of Innate Pharma have been sold short.Short Interest Ratio / Days to CoverInnate Pharma has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Innate Pharma has recently decreased by 18.11%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Innate Pharma this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Innate Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Innate Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.16% of the stock of Innate Pharma is held by institutions.Read more about Innate Pharma's insider trading history. Receive IPHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address IPHA Stock News HeadlinesInnate Pharma Announces Its Participation in Upcoming Investor ConferencesOctober 29, 2024 | businesswire.comInnate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive BoardOctober 14, 2024 | businesswire.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)Leerink Partners Reaffirms Their Buy Rating on Innate Pharma (IPHA)October 9, 2024 | markets.businessinsider.comInnate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024September 30, 2024 | businesswire.comInnate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid TumorsSeptember 23, 2024 | businesswire.comHold Rating on Innate Pharma SA Amid FDA Discussions and Strategic UncertaintiesSeptember 13, 2024 | markets.businessinsider.comInnate Pharma SA: Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business UpdateSeptember 5, 2024 | finanznachrichten.deSee More Headlines IPHA Stock Analysis - Frequently Asked Questions How have IPHA shares performed this year? Innate Pharma's stock was trading at $2.80 at the beginning of the year. Since then, IPHA shares have decreased by 33.0% and is now trading at $1.8750. View the best growth stocks for 2024 here. When did Innate Pharma IPO? Innate Pharma (IPHA) raised $80 million in an initial public offering on Thursday, October 17th 2019. The company issued 10,700,000 shares at a price of $7.50 per share. Citigroup, SVB Leerink and Evercore ISI acted as the underwriters for the IPO. Who are Innate Pharma's major shareholders? Top institutional investors of Innate Pharma include Exchange Traded Concepts LLC (0.10%). How do I buy shares of Innate Pharma? Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Innate Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Innate Pharma investors own include Pfizer (PFE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Altimmune (ALT), Cidara Therapeutics (CDTX) and Fulcrum Therapeutics (FULC). Company Calendar Today11/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IPHA CUSIPN/A CIK1598599 Webwww.innate-pharma.com Phone33-4-30-30-30-30FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Stock Price Target$11.50 High Stock Price Target$11.50 Low Stock Price Target$11.50 Potential Upside/Downside+513.3%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.92 Current Ratio2.92 Quick RatioN/A Sales & Book Value Annual Sales$66.71 million Price / Sales2.28 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book2.72Miscellaneous Outstanding Shares80,970,000Free Float55,147,000Market Cap$151.82 million OptionableNot Optionable Beta0.39 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:IPHA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.